Search
Studies * EuroSIDA * Publications * 2013


EuroSIDA publications 2013

1 Severe bacterial non-AIDS infections in HIV-positive persons: incidence rates and risk factors. OS Søgaard, J Reekie, M Ristola, D Jevtovic, I Karpov, M Beniowski, S Servitskiy, P Domingo, P Reiss, A Mocroft, O Kirk for EuroSIDA in EuroCoord.
J Infect. 2013 May;66(5):439-46. abstract article

2 Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. AD Monforte, P Reiss, L Ryom, W El-Sadr, F Dabis, S De Wit, SW Worm, MG Law, R Weber, O Kirk, C Pradier, AN Phillips, JD Lundgren, CA Sabin.
AIDS. 2013 Jan 28;27(3):407-15. abstract

3 An internationally generalizable risk index for mortality after one year of antiretroviral therapy. JP Tate, AC Justice, MD Hughes, F Bonnet, P Reiss, A Mocroft, J Nattermann, FC Lampe, HC Bucher, TR Sterling, HM Crane, MM Kitahata, M May, J Sterne.
AIDS. 2013 Feb 20;27(4):563-572. abstract article

4 Health care index score and risk of death following TB diagnosis in HIV-positive patients. DN Podlekareva, D Grint, FA Post, A Mocroft, AM Panteleev, RF Miller, JM Miro, M Bruyand, H Furrer, V Riekstina, E Girardi, MH Losso, JA Caylá, EA Malashenkov, N Obel, AM Skrahina, JD Lundgren, O Kirk and the HIV/TB study group.
Int J Tuberc Lung Dis. 2013 Feb;17(2):198-206. abstract

5 Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. Pursuing Later Treatment Option II (PLATO II) Project Team of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE).
J Infect Dis. 2013 Mar;207(5):759-67.abstract article

6 Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and N. America 2002-2009. The Antiretroviral Therapy Cohort Collaboration (ART-CC).
AIDS. 13 March 2013. 27(5):803-813. abstract

7 Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: The D:A:D Study.CA Sabin, L Ryom, H Kovari, O Kirk, S de Wit, M Law, P Reiss, F Dabis, C Pradier, W El Sadr, AD Monforte, D Kamara, AN Phillips, JD Lundgren.
J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):456-63. abstract

8 Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. D Grint, L Peters, J Reekie, V Soriano, O Kirk, B Knysz, O Suetnov, A Lazzarin, B Ledergerber, J Rockstroh, A Mocroft A; EuroSIDA in EuroCoord.
HIV Med. 2013 Jul;14(6):370-8. abstract

9 CD4 count and viral load specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. A Mocroft, A Phillips, J Gatell, A Horban, B Ledergerber, K Zilmer, D Jevtovic, F Maltez, O Kirk, J Lundgren.
AIDS. 2013 March 27(6):907-918. abstract

10 Does hepatitis C viremia or genotype predict the risk of mortality in individuals coinfected with HIV? JK Rockstroh, L Peters, D Grint, V Soriano, P Reiss, A d'Arminio Monforte, M Beniowski, MH Losso, O Kirk, B Kupfer, A Mocroft.
Journal of Hepatology. 2013 Aug;59(2):213-20. abstract

11 Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe. L Ryom, O Kirk, J Lundgren, P Reiss, C Pedersen, S De Wit, S Buzunova, J Gasiorowski, J Gatell, A Mocroft; EuroSIDA in EuroCoord.
HIV Medicine. 2013 Sep;14(8):503-8. abstract

12 Association Between Antiretroviral Exposure and Renal Impairment Among HIV-positive Persons with Normal Baseline Renal Function: the D:A:D study. L Ryom, A Mocroft, O Kirk, SW Worm, DA Kamara, P Reiss, M Ross, CA Fux, P Morlat, O Moranne, C Smith, JD Lundgren; on behalf of the D:A:D study group.
J Infect Dis. 2013 May;207(9):1359-1369. abstract

13 Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-related Death in HIV/Viral Hepatitis Coinfected Patients. L Peters, A Mocroft, V Soriano, J Rockstroh, A. Rauch, A Karlsson, B Knysz, C Pradier, K Zilmer, JD Lundgren, for EuroSIDA in EuroCoord.
PloS One. 2013 May 27;8(5):e64283. doi: 10.1371/journal.pone.0064283.

14 Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study. H Kovari, CA Sabin, B Ledergerber, L Ryom, SW Worm, C Smith, A Phillips, P Reiss, E Fontas, K Petoumenos, S De Wit, P Morlat, JD Lundgren, R Weber.
Clin Infect Dis. 2013 Mar;56(6):870-9. abstract

15 Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). A Mocroft, JD Lundgren, M Sabin, A d'Arminio Monforte, N Brockmeyer, J Casabona, A Castagna, D Costagliola, F Dabis, S De Wit, G Fätkenheuer, H Furrer, AM Johnson, O Kirk, for the Late Presenters Working Group, on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord.
PLoS Med. 2013 10(9): e1001510. online article

16 Insurability of HIV positive people treated with antiretroviral therapy in Europe: Collaborative analysis of HIV cohort studies. J Kaulittz-Bartz J, W Dam, MT May, B Ledergerber, U Widmer, AN Phillips, S Grabar, A Mocroft et al.
AIDS. 2013 Jun 19;27(10):1641-1655.

17 The incidence of AIDS defining illnesses (ADIs) at a current CD4 count > 200/mm3 in the post combination antiretroviral therapy era. A Mocroft, HJ Furrer, J Miro, P Reiss, C Mussini, O Kirk et al. for COHERE in EuroCoord.
Clin Inf Dis 2013 ;57(7):1038-1047

18 Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. SW Worm, M Bower, P Reiss, F Bonnet, M Law, G Fätkenheuer, A d'Arminio Monforte, DI Abrams, A Grulich, E Fontas, O Kirk, H Furrer, S De Wit, A Phillips, JD Lundgren, CA Sabin.
BMC Infect Dis. 2013 Oct 9;13(1):471. PMID:24106926. abstract

19 Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. D Grint, L Peters, C Schwarze-Zander, M Beniowski, C Pradier, M Battegay, D Jevtovic, V Soriano, JD Lundgren, JK Rockstroh, O Kirk and A Mocroft for EuroSIDA in EuroCoord.
HIV Medicine. 2013 Nov;14(10):614-23. abstract

20 Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC) MT May, SM Ingle, D Costagliola, AC Justice, F de Wolf, M Cavassini, A d'Arminio Monforte, J Casabona, RS Hogg, A Mocroft, FC Lampe, F Dabis, G Fätkenheuer, TR Sterling, J del Amo, MJ Gill, HM Crane, MS Saag, J Guest, H Brodt, JAC Sterne and the Antiretroviral Cohort Collaboration.
Int'l J of Epidemiology 2013;1-12. article

21 Multi-drug-resistant tuberculosis in HIV positive patients in Eastern Europe. FA Post, D Grint, AM Werlinrud, A Panteleev, V Riekstina, EA Malashenkov, A Skrahina, D Duiculescu, D Podlekareva, I Karpov, V Bondarenko, N Chentsova, J Lundgren, A Mocroft, O Kirk, JM Miro; HIV-TB Study Group.
J Infect. 2013 Nov 16. article

22 TB Meningitis in HIV-positive patients in Europe and Argentina - Clinical outcome and factors associated with mortality. AM Werlinrud Efsen, A Panteleev, D Grint, DN Podlekareva, A Vassilenko, A Rakhmanova, I Zeltina, MH Losso, R Miller, E Girardi, J Caylá, F Post, JM Miro, M Bruyand, H Furrer, N Obel, JD Lundgren, A Mocroft, O Kirk, and the HIV/TB study group.
BioMed Research International. Sept 2013. article

23 Associations between immune depression and cardiovascular events in HIV infection. CA Sabin, L Ryom, S De Wit, A Mocroft, AN Phillips, SW Worm, R Weber, AD Monforte, P Reiss, D Kamara, W El-Sadr, C Pradier, F Dabis, M Law, J Lundgren.
AIDS. 2013 Nov 13;27(17):2735-48. abstract




Total EuroSIDA publications as of December 2013: 198

Godsexliv.com